Carcinoma, Non-Small-Cell Lung Clinical Trial
— TOP0706Official title:
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC).
Verified date | January 2015 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Src expression has been identified in a majority of Non-Small Cell Lung Cancer (NSCLC) cell
lines and there is preclinical evidence that Src family kinases may be important in hypoxic
growth and angiogenesis in NSCLC. We hypothesize that the inhibition of Src pathway with
dasatinib will demonstrate anti-tumor activity in early stage NSCLC, with a tolerable safety
profile.
Patients will receive dasatinib, a Src inhibitor, for 3 weeks prior to surgical resection
for early stage NSCLC. Fresh frozen tumor tissue is needed for genomic analysis. If fresh
frozen tumor tissue is not available from the initial diagnosis, a biopsy will be required
to participate in this trial. A second tumor sample will be obtained at time of surgical
resection to evaluate for changes in genomic expression profiles.
Patients will be eligible to receive 3 months of adjuvant dasatinib therapy after completion
of standard adjuvant therapy or after recovery from surgery if no standard adjuvant therapy
is given, if there is evidence of neoadjuvant tumor response (radiologic and/or pathologic)
to dasatinib.
Many patients who present with NSCLC are active smokers. Patients who are smoking up until
the time of their surgery experience increased peri-operative complications compared to
patients who have not smoked cigarettes immediately prior to surgery. While this trial will
not be limited to active smokers, the period of smoking cessation prior to surgery is an
attractive window of opportunity during which the potentially active novel anticancer
therapy dasatinib can be offered to the patient.
Status | Terminated |
Enrollment | 2 |
Est. completion date | September 2009 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Suspected or histological/cytological diagnosis of Non-Small Cell Lung Cancer (NSCLC), Stage IB (=4 cm per CT) or Stage IIA or IIB, amenable to surgical resection - Must be deemed a surgical candidate - Tumors =2 cm in maximum diameter without radiographic, bronchoscopic or pathologic evidence of nodal metastases are eligible for biopsy - Fresh tissue biopsy material must be available for genomics analysis prior to initiating dasatinib therapy - Age =18 years - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 - No prior chemotherapy, immunotherapy, radiation therapy or biologic/targeted therapy for any malignancy - Adequate Organ Function: - Total bilirubin <institutional upper limit normal (ULN) - Hepatic enzymes (AST, ALT) =2.5x institutional ULN - Serum creatinine <1.5x institutional ULN - Hemoglobin =9 gm/dL - Neutrophil count (ANC or AGC) =1500 per µL - Platelets =100,000 per µL - Prothrombin time (PT)/a partial thromboplastin time (PTT) =1.5x control - No other serious medical or psychiatric illness - Ability to take oral medication (dasatinib must be swallowed whole) - Women of childbearing potential (WOCBP) must have a negative serum pregnancy test preferably within 72 hours and no later than 7 days, prior to the start of study drug administration - Both sexually active males and females of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped - Signed written informed consent including Health Insurance Portability and Accountability Act (HIPAA) according to institutional guidelines Exclusion Criteria: - Previous or concomitant malignancy in the past 2 years other than curatively treated carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin - Prior dasatinib therapy - Evidence of pleural or pericardial effusion of any grade - Cardiac Symptoms: - Uncontrolled angina, congestive heart failure (CHF), or myocardial infarction (MI) within 6 months - Diagnosed congenital long QT syndrome - Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes) - Prolonged QT corrected (QTc) interval on pre-entry EKG (>450 msec) - Uncontrolled hypertension defined as >160/90 on a regimen of antihypertensive therapy - Subjects with hypokalemia or hypomagnesaemia if it cannot be corrected - History of diagnosed congenital acquired bleeding disorders (e.g., von Willebrand's disease) - Ongoing or recent (=3 months) significant (=grade 3) gastrointestinal bleeding - Concomitant Medications: - Drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib) **quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycin, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine - Current therapeutic dose heparin or coumadin therapy - St. John's Wort and all herbal supplements must be stopped while on dasatinib - IV bisphosphonates will be withheld for 2 weeks prior and 6 weeks after dasatinib administration due to risk of hypocalcaemia - Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness - Pregnant or breastfeeding - Active or uncontrolled infection requiring intravenous antibiotics - Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dasatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) - Patients who have received investigational drugs =4 weeks prior to starting study drug and/or who have not recovered from side effects of such therapy |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | Bristol-Myers Squibb |
United States,
Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D'Amico M, Pestell RG, West M, Nevins JR. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet. 2003 Jun;34(2):226-30. — View Citation
Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006 Nov;12(11):1294-300. Epub 2006 Oct 22. Erratum in: Nat Med. 2007 Nov;13(11):1388. Nat Med. 2008 Aug;14(8):889. Retraction in: Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Nat Med. 2011 Jan;17(1):135. — View Citation
Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006 Aug 10;355(6):570-80. Erratum in: N Engl J Med. 2007 Jan 11;356(2):201-2. Retraction in: Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. N Engl J Med. 2011 Mar 24;364(12):1176. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate | Response rate (radiologic and pathologic) in Stage IB and II to neoadjuvant dasatinib | First progression and survival every 3 months for 2 years, then every 6 months until 5 years, then yearly. | No |
Secondary | Safety and Tolerability of Neoadjuvant Dasatinib | Determine the safety and tolerability of neoadjuvant dasatinib in early stage NSCLC. | Screening / Baseline; Neoadjuvant dasatinib Cycle 1 Day 1 and Day 22 | Yes |
Secondary | Gene Expression Profile Activation of Src Pathways | Determine whether gene expression profile activation of Src pathways is correlated with anti-tumor activity of dasatinib in early stage NSCLC. | Baseline and after 3 weeks of dasatinib therapy at the time of definitive surgical resection. | No |
Secondary | Safety and Tolerability of Adjuvant Dasatinib | Determine the safety and tolerability of adjuvant dasatinib in early stage NSCLC. | Duration of adjuvant treatment plus 30 days. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |